ESR1 and breast cancer: To further investigate ERα signaling, we used ChIP‐seq to evaluate E2‐treated breast cancer PDEs and compared whole‐genome ERα binding events with primary breast cancer tissues and traditional breast cancer models, including the most commonly used ERα‐positive breast cancer cell line, MCF7, grown in vitro or in vivo as xenografts.